Phase 1b Study of Furmonertinib in NSCLC Patients with Exon 20 Insertion Mutation
Allist Pharmaceuticals is conducting a phase 1b trial to evaluate Furmonertinib Mesilate in 30 NSCLC patients with EGFR exon 20 insertion mutations, focusing on efficacy and safety.